TrialRespiratory research2020

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial.

Aili L Lazaar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.